nach oben

Current Infectious Disease Reports

Erschienen in:

21.06.2017 | Respiratory Infections (F Arnold, Section Editor)

The Use of Statins and Risk of Community-Acquired Pneumonia

verfasst von: Mohammed A. Batais, Abdur Rahman Khan, Aref A. Bin Abdulhak

Erschienen in: Current Infectious Disease Reports | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

Community-acquired pneumonia (CAP) is still associated with a large burden and causes significant morbidity and mortality. Besides universal vaccination and antibiotic treatment, statins as adjunctive therapy may also have a beneficial role in the prevention and treatment of CAP. Our goal from this review is to discuss the epidemiology of CAP, and role of statins as adjunctive therapy in the development of CAP.

Recent Findings

Statins are lipid-lowering medications characterized by their ability to control hypercholesterolemia in addition to other pleiotropic effects that could explain their role in the pathogenesis of CAP. While most observational studies have shown that statins reduce risk of pneumonia in the general population, patients with diabetes, and recently in patients with myocardial infarction, no randomized controlled trial (RCT) to date has been conducted to assess the efficacy of statins to prevent development of CAP.

Summary

Given the paucity of robust randomized evidence to assess statin use and the development of CAP, and considering conflicting results of the observational studies, we are not in favor of initiation of statins for either the prevention or treatment of CAP.

Steel HC, et al. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediat Inflamm. 2013;2013

Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014;371(17):1619–28.CrossRefPubMed

Feldman C, Anderson R. Community-acquired pneumonia: still a major burden of disease. Curr Opin Crit Care. 2016;22(5):477–84.CrossRefPubMed

Faverio P and Restrepo MI. Non-antibiotic therapies for CAP. European Respiratory Monograph 63: Community-Acquired Pneumonia, 2014. 63.

Khan, A.R., et al., The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis. PLoS One, 2013. 8(1): p. e52929.

Hou W, et al.. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. European heart journal, 2013: p. eht065.

Gutierrez J, et al. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172(12):909–19.CrossRefPubMed

GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.Lancet 2015; 385: 117–71.

Jain S, et al. Community-acquired pneumonia requiring hospitalization among US children. N Engl J Med. 2015;372(9):835–45.CrossRefPubMedPubMedCentral

10.

McLaughlin JM, et al. Clinical and economic burden of community-acquired pneumonia in the Veterans Health Administration, 2011: a retrospective cohort study. Infection. 2015;43(6):671–80.CrossRefPubMedPubMedCentral

11.

Rozenbaum MH, et al. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims database analysis. Vaccine. 2015;33(28):3193–9.CrossRefPubMed

12.

• Quan TP, et al. Increasing burden of community-acquired pneumonia leading to hospitalisation, 1998–2014. Thorax. 2016;71(6):535–42. This is an important reference that showed rapid increasing of CAP hospitalizations since 2008 in one UK region (Oxfordshire). CrossRefPubMedPubMedCentral

13.

Morimoto K, et al. The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLoS One. 2015;10(3):e0122247.CrossRefPubMedPubMedCentral

14.

Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8(10):776–87.CrossRefPubMedPubMedCentral

15.

Feldman C, Anderson R. Community-acquired pneumonia: pathogenesis of acute cardiac events and potential adjunctive therapies. CHEST Journal. 2015;148(2):523–32.CrossRef

16.

Statt S, et al. Statin-conferred enhanced cellular resistance against bacterial pore-forming toxins in airway epithelial cells. Am J Respir Cell Mol Biol. 2015;53(5):689–702.CrossRefPubMedPubMedCentral

17.

McDowell A, S, et al. Simvastatin is protective during Staphylococcus aureus pneumonia. Curr Pharm Biotechnol. 2011;12(9):1455–62.

18.

Shyamsundar M, et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med. 2009;179(12):1107–14.CrossRefPubMedPubMedCentral

19.

Quinton T, et al. Lipid rafts are required in Gαi signaling downstream of the P2Y12 receptor during ADP-mediated platelet activation. J Thromb Haemost. 2005;3(5):1036–41.CrossRefPubMed

20.

Matarazzo S, et al. Cholesterol-lowering drugs inhibit lectin-like oxidized low-density lipoprotein-1 receptor function by membrane raft disruption. Mol Pharmacol. 2012;82(2):246–54.CrossRefPubMed

21.

Marwali MR, et al. Modulation of ADP-induced platelet activation by aspirin and pravastatin: role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and inside-out integrin signaling. J Pharmacol Exp Ther. 2007;322(3):1324–32.CrossRefPubMed

22.

Phillip Owens III,A, Mackman N. The antithrombotic effects of statins. Annu Rev Med. 2014;65:433–45.CrossRefPubMed

23.

Troeman D, et al. The immunomodulatory effects of statins in community-acquired pneumonia: a systematic review. J Infect. 2013;67(2):93–101.CrossRefPubMed

24.

Boyd AR, et al. Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia. BMC Microbiol. 2012;12(1):73.CrossRefPubMedPubMedCentral

25.

Erkkilä L, et al. Effect of simvastatin, an established lipid-lowering drug, on pulmonary chlamydia pneumoniae infection in mice. Antimicrob Agents Chemother. 2005;49(9):3959–62.CrossRefPubMedPubMedCentral

26.

•• Lin C-F, et al. Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study. BMC cardiovascular disorders. 2016;16(1):24. This is a very important reference that provided the first study to assess statins in patients with myocardial infarction. CrossRefPubMedPubMedCentral

27.

Vinogradova Y, Coupland C, Hippisley-Cox J. Risk of pneumonia in patients taking statins: population-based nested case-control study. Br J Gen Pract. 2011;61(592):e742–8.CrossRefPubMedPubMedCentral

28.

Nohria A, et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis. 2009;205(2):517–21.CrossRefPubMed

29.

Subramanian S, et al. High-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statins. J Am Coll Cardiol. 2013;62(25):2382–91.CrossRefPubMed

30.

van de Garde EM, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax. 2006;61(11):957–61.CrossRefPubMedPubMedCentral

31.

Schlienger RG, et al. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacother: J Hum Pharmacol Drug Ther. 2007;27(3):325–32.CrossRef

32.

Myles PR, et al. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2009;18(4):269–75.CrossRefPubMed

33.

Kwong JC, Li P, Redelmeier DA. Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS One. 2009;4(11):e8087.CrossRefPubMedPubMedCentral

34.

Vinogradova Y, Coupland C, Hippisley-Cox J. Risk of pneumonia in patients taking statins: population-based nested case-control study. Br J Gen Pract. 2011;61(592):e742–8.CrossRefPubMedPubMedCentral

35.

Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 2009;67(1):99–109.CrossRefPubMedPubMedCentral

36.

Nielsen AG, et al. The impact of statin use on pneumonia risk and outcome: a combined population-based case-control and cohort study. Crit Care. 2012;16(4):R122.CrossRefPubMedPubMedCentral

37.

Dublin S, et al. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ. 2009;338:b2137.CrossRefPubMedPubMedCentral

38.

Novack V, et al. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. Can Med Assoc J. 2012;184(7):E367–72.CrossRef

39.

Härkänen M, et al. Patient-specific risk factors of adverse drug events in adult inpatients—evidence detected using the Global Trigger Tool method. J Clin Nurs. 2015;24(3–4):582–91.CrossRefPubMed

40.

• Havers F, et al. Statin use and hospital length of stay among adults hospitalized with community-acquired pneumonia. Clinical Infectious Diseases. 2016;62(12):1471–8. This is an important reference that determined whether statin use was associated with improved outcomes among adults hospitalized with CAP, including those with severe pneumonia, by comparing hospital length of stay (LOS) and in-hospital mortality between statin users and non-users. CrossRefPubMed

41.

•• Viasus D, et al. The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. BMJ open. 2015;5(1):e006251. This randomized controlled trail is a very important reference that determines whether statin therapy given to hospitalized patients with CAP improves clinical outcomes and reduces the concentration of inflammatory cytokines. CrossRefPubMedPubMedCentral

42.

Kwok CS, et al. Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies. Eur J Clin Pharmacol. 2012;68(5):747–55.CrossRefPubMed

43.

Chopra V, et al. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med. 2012;125(11):1111–23.CrossRefPubMed

Titel: The Use of Statins and Risk of Community-Acquired Pneumonia
verfasst von: Mohammed A. Batais
Abdur Rahman Khan
Aref A. Bin Abdulhak
Publikationsdatum: 21.06.2017
Verlag: Springer US
Erschienen in: Current Infectious Disease Reports / Ausgabe 8/2017
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-017-0581-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen